6,969 reports of this reaction
14.2% of all GALCANEZUMAB GNLM reports
#1 most reported adverse reaction
INJECTION SITE PAIN is the #1 most commonly reported adverse reaction for GALCANEZUMAB GNLM, manufactured by Eli Lilly and Company. There are 6,969 FDA adverse event reports linking GALCANEZUMAB GNLM to INJECTION SITE PAIN. This represents approximately 14.2% of all 49,086 adverse event reports for this drug.
Patients taking GALCANEZUMAB GNLM who experience injection site pain should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INJECTION SITE PAIN is a frequently reported adverse event for GALCANEZUMAB GNLM, accounting for a significant proportion of all reports.
In addition to injection site pain, the following adverse reactions have been reported for GALCANEZUMAB GNLM:
The following drugs have also been linked to injection site pain in FDA adverse event reports:
INJECTION SITE PAIN has been reported as an adverse event in 6,969 FDA reports for GALCANEZUMAB GNLM. This does not prove causation, but indicates an association observed in post-market surveillance data.
INJECTION SITE PAIN accounts for approximately 14.2% of all adverse event reports for GALCANEZUMAB GNLM, making it one of the most commonly reported side effect.
If you experience injection site pain while taking GALCANEZUMAB GNLM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.